Prevention of Emergence Agitation in Rhinoplasty With Subanesthetic Propofol and Single-Dose Dexmedetomidine: A Prospective Double-Blind Clinical Study
Dexmedetomidine: In rhinoplasty, 10 minute infusion of 0,5 mcg/kg dexmedetomidine will be administered after nasal packing
Propofol: In rhinoplasty, 0,5 mg/kg propofol IV bolus will be administered after nasal packing
Study summary
To compare of prevention of emergence agitation in rhinoplasty with subanesthetic propofol and single dose dexmedetomidine
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Patients scheduled for rhinoplasty
* Between 18-65 years
* ASA I-II group
Exclusion Criteria:
* Those who are outside the age range of 18-65
* Those who are ASA III and above
* Those with renal,hepatic, cardiac and respiratory diseases
* Those with a known allergy to the medication to be used
* Those who underwent urinary catheterization
Primary outcome measure(s)
Agitation status — 1. minute after extubation The effect on prevention of emergence agitation of propofol and dexmedetomidine will be evaluated by an anaesthetist with the Richmond Agitation Sedation Scale (RASS) at 1 minute after extubation
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.